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Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and 
mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the 
risks for both all cause and cardiovascular (CV) deaths. 
Methods:  Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 
European Society of Cardiology (ESC) guidelines are associated to a lower rate of adverse 
outcomes. Data were obtained from REPOSI, a prospective observational study enrolling 
inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis 
were analysed.   
Results: Among 2,535 patients, 558 (22.0%) were discharged with a diagnosis of AF. Based on ESC 
guidelines, 40.9% of patients were on guideline-adherent thromboprophylaxis, 6.8% were 
overtreated and 52.3% undertreated. Logistic analysis showed that increasing age (p=0.01), heart 
failure (p=0.04), coronary artery disease (p=0.013), peripheral arterial disease (p=0.03) and 
concomitant cancer (p=0.003) were associated with non-adherence to guidelines. Specifically, 
undertreatment was significantly associated with increasing age (p=0.001) and cancer (p<0.001), 
and inversely associated with HF (p=0.023). 
AF patients who were guideline adherent had a lower rate of both all-cause death (p=0.007) and 
CV death (p=0.024) compared to those non-adherent. Kaplan-Meier analysis shows that guideline-
adherent patients had a lower cumulative risk for both all-cause (p=0.002) and CV deaths 
(p=0.011). On Cox regression analysis, guideline adherence was independently associated with a 
lower risk of all-cause and CV deaths (p=0.019 and p=0.006).   
Conclusions: Non-adherence to guidelines is highly prevalent among elderly AF patients, despite 




































































deaths. Efforts to improve guideline adherence would lead to better outcomes for elderly AF 
patients. 





































































The incidence and prevalence of atrial fibrillation (AF) have progressively increased over the last 
20 years, especially in the elderly [1, 2]. In patients aged ≥65 years, the prevalence of AF has more 
than doubled from 1993 to 2007[1]. Because many patients are asymptomatic, guidelines now 
recommend screening for AF in all subjects age 65 and over[3].  
AF is associated with an increased risk for both thromboembolic events and mortality, whether all-
cause or from cardiovascular (CV) causes[1, 4]. Oral anticoagulant (OAC) therapy significantly 
reduces the risk of thromboembolism and mortality amongst AF patients[4]. Both OAC persistence 
and good quality anticoagulation control reduce major adverse events among AF patients[5–8].    
Nonetheless, physician attitudes towards prescribing OAC and their adherence to guidelines 
vary[9].  Recent data from the EURObservational Research Programme AF (EORP-AF) Pilot Registry 
reported that up to 40% of patients managed by European cardiologists are non-adherent to the 
European Society of Cardiology (ESC) guidelines, and that both under- and overtreatment were 
associated with worst outcomes[10]. Elderly patients seem to be less likely to be treated with 
OAC, due to their perceived frailty and higher risk of bleeding[11].  When properly prescribed, OAC 
thromboprophylaxis using a vitamin K antagonist (VKA, e.g. warfarin) with good anticoagulation 
control is associated with better outcomes, even amongst the elderly[11, 12]. 
The aims of this study were as follows: i) to assess physician adherence to guidelines in a cohort of 
Italian AF elderly patients admitted acutely to Italian internal medicine and geriatric wards; ii) to 
describe the main factors associated with guideline non-adherence; and iii) to evaluate the risk of 







































































We studied an elderly AF population from the REPOSI (REgistro POliterapie SIMI) study[13].  The 
latter is a multicentre collaborative observational registry jointly held by the Italian Society of 
Internal Medicine (SIMI), the Ca’ Granda Maggiore Policlinico Hospital Foundation and the Mario 
Negri Institute of Pharmacological Research and based on a network of both internal medicine and 
geriatric wards in Italy and Spain. Full details on the study design and specific aims have been 
reported[13].  
 
Briefly, REPOSI was held for four non-consecutive years: 2008, 2010, 2012 and 2014. In each of 
those years over a period of 4 weeks, quarterly (i.e. February, June, September and December), 
consecutive patients admitted to the participating wards aged more than 65 years were enrolled.  
For the present study, only patients enrolled in the 2012 and 2014 study cohorts were considered, 
as data recorded were more comprehensive than those initially collected in 2008 and 2010.  The 
study protocol was first approved by the Ethics Committee of the Ca’ Granda Maggiore Policlinico 
Hospital Foundation, then ratified for every enrolling site by local Ethics Committee. The study was 
conducted according to Good Clinical Practice recommendations and the Declaration of Helsinki. 
Patients were selected according to the International Classification of Diseases – 9th Edition (ICD-9) 
system. For the purposes of this analysis, all patients discharged with the 427.31 ICD-9 code, 
corresponding to AF diagnosis, were considered. 
 
Thromboembolic risk was defined according to the CHA2DS2-VASc score[4], that defines ‘Low risk’ 
patients males with a CHA2DS2-VASc 0 or females with a CHA2DS2-VASc equal to 1; ‘moderate risk’, 




































































≥2[4]. Given the inclusion criteria (i.e. age ≥65), no patients with low risk were included in this 
analysis. 
 
Guideline adherence was defined according to ESC 2012 Guidelines[3]. AF patients at moderate or 
high risk treated with OAC alone were considered as guideline adherent. Undertreatment was 
defined for patients at moderate or high risk not treated with any OAC or treated with antiplatelet 
drugs (AP); conversely, overtreatment was considered for all patients, both with moderate or high 
risk, treated with OAC plus AP[3]. Medication use was assessed according to the Anatomic 
Therapeutic Chemical (ATC) Classification System. As reported in the Supplementary Materials, 
treatment with AP was defined according to for ATC codes B01AC* and N02BA01, while treatment 
with OAC was defined according to ATC codes B01AA* and B01AE*.  
 
Concomitant diagnoses were evaluated according to the ICD-9 codes as reported in the 
Supplementary Materials. Interactions of comorbidities were evaluated by the Cumulative Illness 
Rating Scale (CIRS) severity index and comorbidity Index[14, 15]. Polypharmacy was defined for 
the contemporary use of 5 or more drugs[13]. Cognitive status was evaluated with the short 
blessed test[16]; elderly depression was investigated with the geriatric depression scale[17].  
Functional status was assessed with the Barthel index[18].  
 
Follow-up data were collected at 3 and 12 months after discharge through telephone interview or, 
if patients were not alive, data were collected from the next of kin. According to death causes 
reported into the electronic case report form, based on investigator judgement.  A CV death was 
defined when it was related to any cardiac or vascular reason. Both all-cause and CV deaths were 






































































All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with 
normal distribution were expressed as means and standard deviations (SD), and tested for 
differences with the Student t test. Non-normal variables were expressed as medians and 
interquartile ranges (IQR) and differences tested with the Mann-Whitney U test. Categorical 
variables, expressed as counts and percentages, were analysed by a chi-square test. 
 
A regression analysis was performed to establish clinical factors significantly associated with 
guideline non-adherence, undertreatment or overtreatment. All variables with a p<0.10 in the 
comparison between the two groups at the baseline were included in a univariate analysis and 
those univariate predictors with a statistical significance of less than 10% were included into a 
forward multivariate logistic model.  
 
A logistic regression analysis was also performed (adjusted for CIRS severity index, CIRS 
comorbidity Index and thromboembolic risk) in order to establish the association between 
undertreatment and study outcomes. This analysis was not performed for the overtreatment 
group, given the very small number of events recorded in this group. 
 
A survival analysis was performed both according to parametric and semi-parametric methods, 
comparing guideline adherence or non-adherence. A log-rank test was performed to establish 
whether or not there was a difference in survival between the two groups. A Cox regression 




































































also performed and survival curves plotted. A two-sided p value <0.05 was considered statistically 




Of the 2,535 patients enrolled in the 2012 and 2014 cohorts, 558 (22.0%) were discharged with a 
diagnosis of AF (median [IQR] age: 82 [76-90] years, 297 [53.2%] females). Amongst AF patients, 
hypertension was the most common risk factor (n=471, 84.4%) [Table 1]. Median [IQR] CHA2DS2-
VASc score was 4 [3-5], with 554 patients (99.3%) being at high thromboembolic risk.  
 
Antithrombotic prophylaxis amongst patients at high thromboembolic risk is shown in Figure 1.  
Among the patients at high thromboembolic risk, only 41.0% were treated with OAC, while 6.7% 
were treated with OAC plus AP.  Of those treated with OAC, 223 out of 227 (97.8%) patients were 
treated with a VKA and only 5 (2.2%) with a non-vitamin K antagonist oral anticoagulant (NOAC); 
all patients treated with OAC plus AP used a VKA.  
 
Based on the 2012 ESC guidelines, only 40.9% (n=228) of the patients were guideline-adherent, 
while 52.3% (n=292) were undertreated and 38 (6.8%) were overtreated. Baseline characteristics 
according to guidelines adherence or non-adherence status are in Table 1. Guidelines-adherent 
patients were younger (p=0.005) and had a lower CIRS severity index (p=0.046). Guideline-
adherent patients also had more HF (p=0.014) but less CAD (p=0.005), PAD (p=0.009) and cancer 
(p=0.002). Functional status indexes were similar in both groups.  
 




































































Multivariable logistic analysis showed that age (odds ratio [OR]: 1.03 per year, 95% confidence 
interval: 1.01-1.06, p=0.01), concomitant diagnoses of CAD (OR: 1.71, 95% CI: 1.12-2.61, p=0.04), 
PAD (OR: 5.25, 95% CI: 1.18-23.41, p=0.03) and cancer (OR: 2.31, 95% CI: 0.47-0.98, p=0.03) were 
significantly associated with guideline non-adherence. Concomitant diagnosis of HF (OR: 0.68, 95% 
CI: 0.47-0.98, p=0.04) was inversely associated with guideline non-adherence. 
 
Undertreatment was significantly associated with increasing age (p=0.001) and concomitant 
diagnosis of cancer (p<0.001) and inversely associated with HF (p=0.023) (Table 2). Increasing age 
(p=0.036), female sex (p=0.023) and COPD diagnosis (p=0.007) were inversely associated with 
overtreatment (Table 2). A clinical history of CAD (p<0.001), PAD (p=0.015) and stroke/TIA 
(p=0.004) were positively associated with overtreatment (Table 2). 
 
Survival Analysis 
In the overall cohort, follow-up data for at least one follow-up time point were available in 74.6% 
patients (n=416). No major differences were found when compared with lost at follow-up 
patients, except for CIRS severity index and alcohol consumption that were lower in patients lost 
to follow-up (see Table S1 in Supplementary Materials).  
Median [IQR] follow-up time was 115 [98-371] days. A total of 73 (13.1%) all-cause deaths and 27 
(4.8%) CV deaths were recorded.  Guideline non-adherent patients had higher rates for all-cause 
(8.9% vs. 3.4%, p=0.007 vs. guideline adherent) and CV death (21.9% vs. 11.7%, p=0.024 vs. 
guideline adherent). No significant difference was detected in rates of non CV death (13.1% vs. 
8.4% for guideline non-adherent vs. adherent patients; p=0.130).  Undertreatment was 
significantly associated with all-cause deaths (OR: 2.30, 95% CI: 1.32-4.02, p=0.003) and CV deaths 




































































adjustment for CIRS severity index, CIRS comorbidity Index and thromboembolic risk (OR: 2.78, 
95% CI: 1.07-7.23, p=0.036 and OR: 2.12, 95% CI:1.21-3.72, p=0.009, respectively). 
 
Kaplan-Meier curves show that guideline-adherent patients had a lower cumulative risk for both 
all-cause deaths (Log-Rank: 9.631, p=0.002) and CV deaths (Log-Rank: 6.497, p=0.011) compared 
to guideline non-adherent patients [Figure 2].  Cox regression analysis shows that guideline 
adherent patients had a lower risk for all-cause death (HR: 0.47, 95% CI: 0.29-0.81, p=0.006) and 
CV death (hazard ratio [HR]: 0.33, 95% CI: 0.13-0.83, p=0.019) even after adjustment for CIRS 
severity index, CIRS comorbidity index and thromboembolic risk. 
 
DISCUSSION 
The principal findings of this study are that firstly, almost 60% of Italian elderly patients with AF 
were managed with a guideline non-adherent approach for OAC, with most being undertreated 
(52.3%).  Second, the main clinical factors associated with guideline non-adherence were older age 
and a clinical history of HF, CAD and PAD, as well as the concomitant diagnosis of cancer. In 
particular, increasing age was associated with undertreatment, along and the diagnosis of cancer, 
while HF was inversely associated with undertreatment.  Conversely, a younger age, female sex 
and a previous history of CAD, PAD and stroke/TIA were associated with overtreatment with 
concomitant OAC and AP.  Third, undertreatment was associated with a significant risk for both 
all-cause and CV deaths, whilst guideline-adherent AF patients had a lower risk for both endpoints. 
 
In this study, the percentage of AF patients treated with a guideline-adherent approach was lower 
than in previous reports[10, 19]. More recently, the EURObservational Research Programme AF 




































































guideline-adherent in 60.6%.  The EORP-AF reflected patient management by European 
cardiologists from both in- and outpatient settings, whilst in the REPOSI study all the in-patients 
enrolled were elderly and from internal medicine or geriatric wards. 
 
In the EORP-AF ancillary analysis on guidelines adherence, the South European region (which 
included Italy) was associated with undertreatment, confirming several previous reports of a 
significantly low rate of patients treated with OAC among Italian AF patients[20–24]. This seems to 
occur despite several reports on effectiveness and safety, showing that elderly patients treated 
with a VKA had a significant benefit in reducing both thromboembolic events and mortality, 
irrespective of age[12]. A recent position paper from the ESC Working Group on Thrombosis also 
stated that whilst elderly patients were underrepresented in various clinical trials investigating 
antithrombotic drugs, OAC treatment with VKA or NOACs was effective and safe in elderly 
patients[25]. The BALKAN-AF survey also reported that age was inversely associated with OAC 
prescription, but was positively associated with undertreatment with AP[26]. 
 
Age and the concomitant diagnosis of cancer were clinical factors associated with guideline non-
adherence in this study while clinical history of HF was inversely associated with guideline non-
adherence, at variance with previous reports such as the EORP-AF registry[10].  Specifically, both 
age and malignancy were significantly associated with undertreatment in REPOSI, while only 
malignancy was associated with undertreatment in the EORP-AF cohort[10].  This perhaps 
suggests that frailty in elderly patient influences physician decision for non-treatment with OAC. 
Similar observations were made in the Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation (ORBIT-AF), where frailty was reported in a large proportion of patients as the main 




































































observational Canadian study in the setting of octogenarian AF patients[28]. In the REPOSI cohort, 
we found no significant difference in functional status indexes (i.e. Barthel Index) between 
patients treated with a guideline-adherent approach and those who were non-guideline adherent. 
 
When investigating factors significantly associated with overtreatment, most AF patients with 
CAD, PAD and Stroke/TIA were overtreated with OAC and AP. Similar findings were also reported 
in the EORP-AF[10] and the BALKAN-AF surveys[26]. This approach seems to be maintained widely 
by physicians despite explicit guideline recommendations to only prescribe OAC for stroke 
prevention in AF patients with stable vascular disease[3, 29].  
 
Our results emphasise the importance of OAC for AF patients in reducing all-cause mortality and 
CV, even in the elderly.  Physician adherence to guidelines in terms of OAC use represents an 
important clinical step.  In the Euro Heart Survey, undertreatment was significantly associated 
with thrombosis-related events, with a 2-fold higher risk compared to a guideline-adherent 
approach[19]. Conversely, undertreatment was associated with an increase in the composite 
outcome of any thromboembolic event, major bleeding and CV death[19]. The analysis from 1-
year follow-up of the EORP-AF study also confirms that both undertreatment and overtreatment 
are associated with higher risk for the composite endpoint of all-cause death plus any 
thromboembolic event, with a more than 60% higher risk for both undertreatment and 
overtreatment[10]. Indeed, undertreatment per se was associated with a higher risk for any 
thromboembolic event (OR: 1.72)[10]. Of note, our results provide a “real world” validation for the 
degree of implementation of the ESC guidelines in a large unselected population of elderly AF 




































































randomized clinical trials specifically evaluating OAC therapy (as discussed above), our data 
strengthen and underscore the necessity for large prospective studies in the elderly AF population. 
 
Limitations 
The main limitation of the study is its observational nature, with relatively limited power to detect 
differences in survival.  Lack of follow-up data for some of our patients represents another 
important limitation and no precise details about the cause(s) of death were obtained. We could 
not evaluate how effective anticoagulation could impact on outcomes occurrence given the 
absence in the registry dataset of any index of anticoagulation control (e.g. time in therapeutic 
range, TTR). Furthermore, evaluation of OAC therapy adequacy based solely on the 
thromboembolic risk assessment may not be comprehensive enough. Possible contraindications 
to OAC therapy, as well as possible comorbidities interacting with OAC (i.e. chronic kidney 
disease), must be taken into account during the prescription process. Finally, given the low 
number of the subgroups considered, our results should be interpreted cautiously.   
 
In conclusion, guideline non-adherence was evident for a large proportion of elderly patients with 
AF. Guideline-adherent treatment was independently associated with a significantly lower risk of 
all-cause and CV death.  Efforts to improve guideline adherence would lead to better outcomes for 
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Table 1: Baseline characteristics at hospital discharge according to guideline adherence 







Age, (years) median [IQR] 82 [76-86] 81 [75-85] 83 [77-87] 0.005 
Female, n (%) 297 (53.2) 122 (53.5) 175 (53.0) 0.911 
Education, (years) median [IQR] 491 5 [5-8] 5 [5-8] 5 [5-8] 0.416 

















Short Blessed Test, median [IQR] 504 8 [4-14] 8 [4-14] 8 [2-15] 0.918 
Geriatric Depression Scale, median [IQR] 460 1 [0-2] 1 [0-2] 1 [0-2] 0.406 
Barthel Index, median [IQR] 434 86 [52-100] 88 [57-100] 83 [52-100] 0.179 








































































































Alcohol Consumption, n (%) 540 236 (43.7) 97 (43.1) 139 (44.1) 0.814 
Polypharmacy, n (%) 546 513 (94.0) 215 (94.3) 298 (93.7) 0.776 
Hypertension, n (%) 471 (84.4) 192 (84.2) 279 (84.5) 0.915 
Hypercholesterolemia, n (%) 45 (8.1) 22 (9.6) 23 (7.0) 0.253 
Heart Failure, n (%) 185 (33.2) 89 (39.0) 96 (29.1) 0.014 
Coronary Artery Disease, n (%) 137 (24.6) 42 (18.4) 95 (28.8) 0.005 
Myocardial Infarction, n (%) 13 (2.3) 5 (2.2) 8 (2.4) 0.859 
Peripheral Artery Disease, n (%) 18 (3.2) 2 (0.9) 16 (4.8) 0.009 
Stroke/TIA, n (%) 87 (15.6) 28 (12.3) 59 (17.9) 0.073 
Diabetes, n (%) 184 (33.0) 82 (36.0) 102 (30.9) 0.212 
Chronic Kidney Disease, n (%) 160 (28.7) 66 (28.9) 94 (28.5) 0.905 
COPD, n (%) 144 (25.8) 58 (25.4) 86 (26.1) 0.869 
Cancer, n (%) 76 (13.6) 19 (8.3) 57 (17.3) 0.002 
CHA2DS2-VASc, median [IQR] 4 [2-5] 4 [3-5] 4 [3-5] 0.732 

















































































Table 2: Multivariable logistic regression analysis for undertreatment and overtreatment 
 OR 95% CI p 
Undertreatment    
Age (per year) 1.05 1.02-1.07 0.001 
Heart Failure 0.64 0.44-0.94 0.023 
Cancer 2.67 1.53-4.68 0.001 
Overtreatment    
Age (per year) 0.92 0.85-0.99 0.036 
Female  0.32 0.12-0.85 0.023 
Coronary Artery Disease 12.15 4.61-32.03 <0.001 
Peripheral Arterial Disease 28.83 1.91-435.72 0.015 
Stroke/TIA 4.46 1.61-12.32 0.004 
COPD 0.17 0.05-0.62 0.007 
Legend: CI= confidence interval; COPD= chronic obstructive pulmonary disease; OR= odds ratio; 







































































Figure 1: Distribution of antithrombotic treatments in patients with high thromboembolic risk. 
Legend: AP= antiplatelet; OAC= oral anticoagulant; TE= thromboembolic. 
 
Figure 2: Kaplan-Meier curves for major adverse outcomes. 
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